| In ZINC since | Heavy atoms | Benign functionality |
|---|---|---|
| March 2nd, 2009 | 25 | Yes |
Popular Name: FR 180204 FR 180204
Find On: PubMed — Wikipedia — Google
CAS Numbers: 865362-74-9 , [865362-74-9]
| Type pH range | xlogP | Des A‑Pol Apolar desolvation (kcal/mol) | Des Pol Polar desolvation (kcal/mol) | H Don H-bond donors | H Acc H-bond acceptors | Chg Net charge | tPSA (Ų) | MWT Molecular weight (g/mol) | RB Rotatable bonds | DL |
|---|---|---|---|---|---|---|---|---|---|---|
| Ref Reference (pH 7) | 2.85 | 7.16 | -16.7 | 3 | 7 | 0 | 98 | 327.351 | 2 | ↓ |
| Ref Reference (pH 7) | 2.85 | 7.12 | -24.37 | 3 | 7 | 0 | 98 | 327.351 | 2 | ↓ |
| Note Type | Comments | Provided By |
|---|---|---|
| ALOGPS_SOLUBILITY | 4.31e-02 g/l | DrugBank-experimental |
| Target | ERK | Selleck Chemicals |
| Indications | protein kinase inhibitor | KeyOrganics Bioactives |
| Code | Description | Organism Class | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| MK01-1-E | Mitogen-activated Protein Kinase 1 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 310 | 0.36 | Binding ≤ 10μM |
| MK03-1-E | MAP Kinase ERK1 (cluster #1 Of 1), Eukaryotic | Eukaryotes | 310 | 0.36 | Binding ≤ 10μM |
| MK14-1-E | MAP Kinase P38 Alpha (cluster #1 Of 3), Eukaryotic | Eukaryotes | 310 | 0.36 | Binding ≤ 10μM |
| Uniprot | Swissprot | Description | Affinity (nM) | LE (kcal/mol/atom) | Type |
|---|---|---|---|---|---|
| MK03_HUMAN | P27361 | MAP Kinase ERK1, Human | 310 | 0.36 | Binding ≤ 1μM |
| MK01_HUMAN | P28482 | MAP Kinase ERK2, Human | 310 | 0.36 | Binding ≤ 1μM |
| MK14_HUMAN | Q16539 | MAP Kinase P38 Alpha, Human | 310 | 0.36 | Binding ≤ 1μM |
| MK03_HUMAN | P27361 | MAP Kinase ERK1, Human | 310 | 0.36 | Binding ≤ 10μM |
| MK01_HUMAN | P28482 | MAP Kinase ERK2, Human | 1900 | 0.32 | Binding ≤ 10μM |
| MK14_HUMAN | Q16539 | MAP Kinase P38 Alpha, Human | 310 | 0.36 | Binding ≤ 10μM |
| Description | Species |
|---|---|
| activated TAK1 mediates p38 MAPK activation | |
| Activation of PPARGC1A (PGC-1alpha) by phosphorylation | |
| Activation of the AP-1 family of transcription factors | |
| ADP signalling through P2Y purinoceptor 1 | |
| Advanced glycosylation endproduct receptor signaling | |
| CDO in myogenesis | |
| CREB phosphorylation through the activation of Ras | |
| DSCAM interactions | |
| ERK/MAPK targets | |
| ERK1 activation | |
| ERK2 activation | |
| ERKs are inactivated | |
| FCERI mediated MAPK activation | |
| Gastrin-CREB signalling pathway via PKC and MAPK | |
| Golgi Cisternae Pericentriolar Stack Reorganization | |
| Growth hormone receptor signaling | |
| ISG15 antiviral mechanism | |
| KSRP destabilizes mRNA | |
| NCAM signaling for neurite out-growth | |
| Negative regulation of FGFR signaling | |
| NOD1/2 Signaling Pathway | |
| Oncogene Induced Senescence | |
| Oxidative Stress Induced Senescence | |
| p38MAPK events | |
| phospho-PLA2 pathway | |
| Platelet sensitization by LDL | |
| Recycling pathway of L1 | |
| Regulation of actin dynamics for phagocytic cup formation | |
| Regulation of HSF1-mediated heat shock response | |
| RNA Polymerase I Promoter Opening | |
| RSK activation | |
| Senescence-Associated Secretory Phenotype (SASP) | |
| Signal attenuation | |
| Signal transduction by L1 | |
| Signaling by FGFR | |
| Thrombin signalling through proteinase activated receptors (PARs) | |
| VEGFA-VEGFR2 Pathway |
No pre-computed analogs available. Try a structural similarity search.